These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36259026)

  • 1. The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review.
    Sharaf J; Williams KD; Tariq M; Acharekar MV; Guerrero Saldivia SE; Unnikrishnan S; Chavarria YY; Akindele AO; Jalkh AP; Eastmond AK; Shetty C; Rizvi SMHA; Mohammed L
    Cureus; 2022 Sep; 14(9):e29118. PubMed ID: 36259026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Multidisciplinary Management of Perianal Fistulas in Crohn's Disease: A Systematic Review.
    Badla O; Goit R; Saddik SE; Dawood S; Rabih AM; Mohammed A; Raman A; Uprety M; Calero M; Villanueva MRB; Joshaghani N; Villa N; Mohammed L
    Cureus; 2022 Sep; 14(9):e29347. PubMed ID: 36284816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
    Kulisevsky J; Esquivel A; Freire-Álvarez E; Gómez-Esteban JC; Legarda-Ramírez I; Avilés A; Mata-Álvarez-Santullano M
    Rev Neurol; 2023 Oct; 77(s02):1-12. PubMed ID: 37752685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of the effectiveness and safety of safinamide for levodopa-induced motor complications in Parkinson's disease.
    Li J; Zhang J; Meng P
    Biotechnol Genet Eng Rev; 2023 May; ():1-12. PubMed ID: 37232405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
    Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L
    Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide for pain management in patients with Parkinson's disease.
    Abilashimova D; Aubakirova M; Abdildin Y; Viderman D
    Rev Neurol (Paris); 2023 Dec; ():. PubMed ID: 38103994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kano O; Tsuda H; Hayashi A; Arai M
    Parkinsons Dis; 2022; 2022():4216452. PubMed ID: 36081594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study.
    Martí-Andrés G; Jiménez-Bolaños R; Arbelo-González JM; Pagonabarraga J; Duran-Herrera C; Valenti-Azcarate R; Luquin MR
    Brain Sci; 2019 Oct; 9(10):. PubMed ID: 31614574
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.